Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Binds antigen or epitope whose amino acid sequence is...
Patent
1995-06-07
1997-02-11
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Binds antigen or epitope whose amino acid sequence is...
4241451, 4241851, 5303879, 53038825, 5303891, 5303893, 5303873, 530807, 530403, 530328, 530327, A61K 3808, A61K 39385, A61K 39395, C07K 1618
Patent
active
056018215
ABSTRACT:
An immunogen comprising a residue of a histamine-releasing peptide comprising a cationic N-terminal head and a hydrophobic C-terminal tail, together with a residue capable of eliciting antibodies against said peptide while inhibiting histamine release by said peptide is useful in anti-allergy treatment. Preferably the histamine-releasing peptide is of formula:
REFERENCES:
patent: 4161522 (1979-07-01), Hamburger et al.
patent: 4223016 (1980-09-01), Roy et al.
patent: 4579840 (1986-04-01), Hahn
patent: 4683292 (1987-07-01), Hahn
patent: 5283243 (1994-02-01), Jasserand et al.
Lachmann et al, CIBA Symposium 119:25-57 (1986).
K. M. Thompson et al., "The efficient production of stable human monoclonal antibody-secreting hybridomas . . . ", J. Immunol. Methods 94, 7-12 (1986).
H. Bialy, "Quietly rationalizing drug discovery", Biotechnology 11, 1516-1517 (Dec. 1993).
R. M. Channock et al., "Human monoclonal antibody Fab fragments . . . ", Infectious Agents Dis. (USA) 2/3 118-131 (1993), EMBASE online Abstract only.
H. Ditzel et al., "Tumor-detection with I-131 Labelled Human Monoclonal Antibody COU-1 . . . ", Cancer Research 53 (24), 5920-5928 (Dec. 15, 1993), Scisearch online Abstract only.
"Orthoclone OKT3 (muromonab-CD3 murine monoclonal antibody) indications expanded in US", SCRIP, Jul. 6, 1993.
M. J. Elliott et al., "Treatment of Rheumatoid Arthritis with Chimeric Monoclonal Antibodies . . . ", Arthritis & Rheumatism 36 (12), 1681-1690 (1993).
W. E. Brocklehurst, "Passive cutaneous anaphylaxis (PCA)" in Handbook of Experimental Immunology ed. D. M. Weir, 3rd ed., Blackwell (1978), pp. 21.1-21.6.
O. M. Poulsen & J. Hau, "Murine passive cutaneous anaphylaxis test (PCA) for the `all or none` determination of allergenicity of bovine whey proteins and peptides", Clinical Allergy 17, 75-83 (1987).
S. Kitani et al., "Inhibition of allergic reactions with monoclonal antibody to the high affinity of IgE receptor", J. Immunology 140, 2585-2588 (1988).
N. Nio et al., "Inhibition of passive cutaneous anaphylaxis by synthetic human immunoglobulin E peptide fragments", FEBS Letters 314, 229-231 (1992).
B. J. Sutton and H. J. Gould, "The Human IgE network", Nature 386, 421-428, (Dec. 2, 1993).
I. M. Roitt, "Essential Immunology", 6th ed., Blackwell (1988), pp. 193-196.
R. D. Guttmann et al., "Immunology", A Scope Publication, The Upjohn Company (1985), p. 15.
D. A. Moneret-Vautrin et al., "The risk of allergy related to general anaesthesia", Clinical and Experimental Allergy 23, 629-633 (1993), p. 629 only.
F. Leynadier, "Prick tests in the diagnosis of anaphylaxis to general anaesthetics", Br. J. Anaesth. 59, 683-689 (1987), p. 683 only.
M. Fleet, "Hundreds join fight for more research into peanut allergy", The Daily Telegraph, London, Apr. 5, 1994, p. 5.
K. Ramaswamy et al., "IgE antibody responses in bronchoalveolar spaces of rats . . . ", Exp. Parasitol. 76 (1), 23-31 (1993), Medline abstract only.
T. Masumoto et al., "Inhibitory effect of xian-qing-long-tan extract on degranulation and histamine release from rat mast cells", Acta Otolaryngol. Suppl. (Stockholm), 501, 100-102 (1993), Medline abstract only.
K. Ishii et al., "Antiallergic activity and mode of action . . . ", Arzneimittelforschung 43 (2), 148-154 (1993), Medline absrtact only.
C. Ra et al., "Soluble human high-affinity receptor for IgE abrogates the IgE-mediated allergic reaction", Int. Immunol. 5, 47-54 (1993), Medline abstract only.
H. Nagai et al., "Anti-inflammatory properties of zinc protoporphyrin disodium (Zn-PP-2Na)", Agents and Actions 37, 273-283 (1992), Medline abstract only.
W. Elwood et al., "Airway hyperresponsiveness is associated with inflammatory cell . . . ", Int. Arch. Allergy Immunol. 99, 91-97 (1992), Medline abstract only.
T. Nabe et al., "Effect of SA-103 on experimental allergic models", 41, 676-685 (1992), Medline abstract only.
B. Helm et al., "The mast cell binding site on human immunoglobulin E", Nature 331, 180-183 (1988).
D. R. Stanworth et al., "Allergy treatment with a peptide vaccine", The Lancet, 336, 1279-1281 (Nov. 24, 1990).
British Technology Group Information Release "Primate response to anti-allergy vaccine", typescript, 3 pages (Oct. 1991).
M. Z. Atassi (ed.) "Immunochemistry of Proteins", vol. 2, Plenum Press, New York (1977), pp. 293-295.
D. R. Stanworth et al, "Synthetic Peptides Comprising Sequences of the Human Immunoglobulin E Heavy Chain Capable of Releasing Histamine", Biochem. J. 180:665-668 (1979).
Burt et al., Molecular Immunology 24, 379-389 (1987).
Hastings et al., Immunology 65, 149-151 (1988).
Burt et al., Molecular Immunology 23, 181-191 (1986).
Kabat et al., "Sequences of proteins of immunological interest", 4th ed. pp. 323-331, Dept. of Health & Human Services, Public Health Service, National Institutes of Health, Bethesda Md. (1987).
Hellman et al., Nucleic Acids Research 10, 6041-6049 (1982).
Bennich et al., International Archives of Allergy and Applied Immunology 53, 459-468 (1977).
Stanworth et al., "The use of synthetic peptides in the delineation of immunoglobulin antigenic epitopes", Ciba Foundation Symposium 119, 226-244 (1986).
Stanworth et al "Essential Structural Requirements . . . " Molecular Immunology, vol. 21 No. 3, 1984, pp. 243-247.
Stanworth et al "Anti-e-Chain Antibodies . . . " Molecular Immunology, vol. 23 No. 11, 1986, pp. 1231-1235.
Harris et al., TIBTECH, 11:42, 1993, Therapeutic . . . Age.
Osband et al., Immunol. Today, 11:193, 1990, Problems . . . immunotherapy.
Hird et al., Immunotherapy with monoclonal antibodies, in Genes & Cancer, 1990, pp. 184-189.
S.sub.2 --Waldmann Science 252: 1657-1662 1991.
T.sub.1 --Cunningham et al. Tibtech 10:57 1992.
L. Riechmann et al., "Reshaping human antibodies for therapy", Nature 332, 323-327 (1988).
M. K. Church and C. F. Gradidge, "The activity of sodium cromoglycate analogues in human lung in vitro: a comparison with rat passive cutaneous anaphylaxis and clinical efficacy", British Journal of Pharmacology 70, 307-311 (1980).
J. L. Suschitzky and P. Sheard, "The Search for Anti-allergic drugs for the treatment of asthma--problems in finding a successor to sodium cromoglycate" in Progress in Medicinal Chemistry, 21, ed. Ellis & West, Elsevier, 1984, pp. 1-61.
H. Cairns, "Models for the development of anti-asthmatic drugs" in The Mast Cell ed. J. Pepys & A. M. Edwards, Pitman Medical Publishing Co. Ltd 1979, pp. 172-177.
P. Riley et al., Int. Archs. Allergy appl. Immun. 82, 108-110 (1987).
S. Aibara et al., "Antiallergic Activity of 6-(2-Cyclohexylethyl)-[1,3,4]thiadiazolo-[3,2-a]-1,2,3-triazolo-[4,5-d]pyr imidin-9(3H)-one (DS-4574) in Rats" Int. Arch. Allergy Immunol. 98, 146-152 (1992).
C. D. Wegner et al., "The role of 5-lipoxygenase products in preclinical models of asthma", J. Allergy Clin. Immunol. 91 (4) 917-929 (Apr. 1993).
G. Winter et al., "Humanized antibodies", Immunology Today 14 (No. 6), 243-246 (1993).
"Dorland's illustrated Medical Dictionary", 26th ed., pub W. B. Saunders Co. 1981, p. 67.
T. P. Hopp & K. R. Woods, "Prediction of protein antigenic determinants from amino acid sequences", Proc. Natl. Acad. Sci. USA 78, 3824-3828 (1981).
T. A. Waldmann, "The IL-2/IL-2 (sic) receptor system: a target for rational immune intervention", Immunology Today 14 (6), 264-269 (1993).
R. M. Sharkey et al., "Clinical Evaluation of Tumor Targeting with a High-Affinity, Anticarcino embryonic -Antigen-Specific, Murine Monoclonal Antibody, MN14", Cancer 71 (6), 2082-2096 (1993).
A. I. Lazarovits et al., "Human Mouse Chimeric CD7 Monoclonal Antibody (SDZCHH380) for the Prophylaxis of Kidney Transplant Rejection" J. Immunology 150 (11) 5163-5174 (1993).
G. E. Goodman et al., "Phase I trial of chimeric (human-mouse) monoclonal antibody L6 in patients with non- small-cell lung, colon and breast cancer", Cancer Immunology Immunotherapy 36, 267-273 (1993).
Jones Valerie
Lewin Ian V.
Nayyar Sarita
Stanworth Denis R.
Eisenschenk Frank C.
National Research Development Corporation
LandOfFree
Immunoactive peptides and antibodies and their use in anti-aller does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoactive peptides and antibodies and their use in anti-aller, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoactive peptides and antibodies and their use in anti-aller will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-339741